A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered once weekly in patients with solid tumors

Category Primary study
JournalJournal of Clinical Oncology
Year 2010
This article has no abstract
Epistemonikos ID: 81aaa1c50d36ec1979b11004d322795a065f86b2
First added on: Mar 01, 2025